about
Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain managementReducing breast cancer incidence in familial breast cancer: overlooking the present panorama.Prophylactic options in patients with 5-fluorouracil-associated cardiotoxicity.Palliative sedation in patients with advanced cancer followed at home: a systematic review.Triplet chemotherapy in patients with metastatic colorectal cancer: toward the best way to safely administer a highly active regimen in clinical practice.New opioids.Pain characteristics and analgesic treatment in an aged adult population: a 4-week retrospective analysis of advanced cancer patients followed at home.Pattern of symptoms and symptomatic treatment in adults and the aged population: a retrospective analysis of advanced cancer patients followed at home.Age differences in the last week of life in advanced cancer patients followed at home.Epidemiology and Characteristics of Episodic Breathlessness in Advanced Cancer Patients: An Observational Study.Sleep Disturbances in Patients With Advanced Cancer in Different Palliative Care Settings.Fentanyl Buccal Tablet vs. Oral Morphine in Doses Proportional to the Basal Opioid Regimen for the Management of Breakthrough Cancer Pain: A Randomized, Crossover, Comparison Study.Prevalence of oral mucositis, dry mouth, and dysphagia in advanced cancer patients.Pain intensity as prognostic factor in cancer pain management.The frequency of alcoholism in patients with advanced cancer admitted to an acute palliative care unit and a home care program.Tapentadol at medium to high doses in patients previously receiving strong opioids for the management of cancer pain.Orphan symptoms in advanced cancer patients followed at home.Palliative sedation in patients with advanced cancer followed at home: a prospective study.The use of fentanyl buccal tablets for breakthrough pain by using doses proportional to opioid basal regimen in a home care setting.Relationship between background cancer pain, breakthrough pain, and analgesic treatment: a preliminary study for a better interpretation of epidemiological and clinical studies.Opioid switching from and to tapentadol extended release in cancer patients: conversion ratio with other opioids.Tapentadol in cancer pain management: a prospective open-label study.Prognostic factors of survival in patients with advanced cancer admitted to home care.Emergencies in patients with advanced cancer followed at home.Palliative sedation in advanced cancer patients followed at home: a retrospective analysis.The effects of low doses of pregabalin on morphine analgesia in advanced cancer patients.How do cancer patients receiving palliative care at home die? A descriptive study.Does pain intensity predict a poor opioid response in cancer patients?Low doses of transdermal fentanyl in opioid-naive patients with cancer pain.Breakthrough pain in oncology: a longitudinal study.Tools for identifying cancer pain of predominantly neuropathic origin and opioid responsiveness in cancer patients.Switching from transdermal drugs: an observational "N of 1" study of fentanyl and buprenorphine.Use of strong opioids in advanced cancer pain: a randomized trial.Topical Menthol for Treatment of Chemotherapy-induced Peripheral Neuropathy.Caring for Cancer Patients After the Italian Earthquakes: A Proposal From the Field.Integrating oncology and palliative home care in Italy: the experience of the "L'Aquila per la Vita" Home Care Unit.Safety and effectiveness of intravenous morphine for episodic breakthrough pain in patients receiving transdermal buprenorphine.Dosing fentanyl buccal tablet for breakthrough cancer pain: dose titration versus proportional doses.Gabapentin in the treatment of hiccups in patients with advanced cancer: a 5-year experience.Palliative care in advanced cancer patients: how and when? And where?
P50
Q28273281-BEFD71FB-669C-4F25-8E4B-B4C3C74575CCQ35848789-B3182663-A961-4FDA-89E9-8065DDFCC189Q36648933-6155CCA7-C29B-4882-ABE6-D66ABD5FFC36Q37827976-4E107313-5A9B-4538-96B4-1FECF80E0338Q38018403-33F54110-1FFC-4523-AD77-0D5CF0A9B19FQ38209633-3A216FBE-4A19-4047-889A-11784BE247D2Q38398609-8F861A36-BCE5-4344-A827-2391D880FF85Q39177395-0D69BBEC-DB93-4B08-BB5D-3E62581DC653Q39182044-965345BC-6321-473C-B766-0553E9CF1B2FQ39182768-3BB8E2D5-C5A4-43F9-B2C9-32094861DF86Q39184276-ED65EE11-3F92-41D8-9378-A4DE5F3E8CF3Q39184413-8EF90904-FE3A-4DA1-84FE-ED0442C8C633Q39191655-94BB5349-AF7C-46B4-8623-4BF070626241Q39198781-31A3F794-5885-407F-B387-563EA1EF4401Q39204707-01BE15A5-359A-49BD-8F1B-12F86A2832EFQ39205556-3FE75C60-ADA2-4DD5-B8CE-0A55DD9352C9Q39219060-62976772-244B-42A8-BFA0-2DF974323EFEQ39219503-2C5E011A-AD25-42F4-BC3D-7B26F88BC129Q39229449-89B58DB8-1F2C-4610-9CFC-2C97CD9CC902Q39229667-9727C824-17EC-4F2C-B1DD-A3ED5702726FQ39229861-A1D75A88-AC4A-4D6D-A14A-DBA3C63810B7Q39240254-7E8EC459-1B92-4718-839E-08C34C752D76Q39241097-01597C3A-392D-47CB-9BCE-5731569C374DQ39243842-DA7D7643-919C-40CE-8146-36F268509138Q39247068-FDB89D8A-3E32-4A54-BF77-842270F90DD2Q39249089-05AD654C-9050-4441-BEF3-740A77C60E65Q39265201-96FA1E37-B35D-4D3D-A868-558D912EA1D8Q39272665-FAA3D350-F42E-4CF9-A6E2-C0AC29619303Q39277708-6C409892-D647-49CF-AC6D-2EDC034EAEB6Q39286368-06A112CF-3340-43C1-B09C-D0EE3165FD42Q39307343-7A50DA40-A5DB-4ECC-A1E6-90B5BB747216Q39333021-15613534-930D-45E1-BA0E-DCC3DFDEF619Q39381008-313A9C77-179C-4DDB-8B96-432975FC97FFQ41274080-5D3313A7-8E0D-4CC0-8BC4-19920C445DB4Q41936615-19AE3E2C-FF31-4A00-9FD1-5FAA7E8BBE43Q41969019-8E3449B0-83B8-4D16-A628-539FA1C9A50FQ42499020-88D75A37-60CD-4175-BC98-717D37490B97Q42504553-774D1193-7829-4A22-8CD5-92DF63A917D6Q43088064-5AE5D7FA-0B0A-4184-84F1-07A87211DEBAQ43203210-1C5A8AC7-7528-449D-8976-5CE1633175D0
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Giampiero Porzio
@ast
Giampiero Porzio
@en
Giampiero Porzio
@es
Giampiero Porzio
@nl
Giampiero Porzio
@sl
type
label
Giampiero Porzio
@ast
Giampiero Porzio
@en
Giampiero Porzio
@es
Giampiero Porzio
@nl
Giampiero Porzio
@sl
prefLabel
Giampiero Porzio
@ast
Giampiero Porzio
@en
Giampiero Porzio
@es
Giampiero Porzio
@nl
Giampiero Porzio
@sl
P106
P1153
56247862800
P21
P31
P496
0000-0002-9875-9220